Farmacias similares begins expansion to japan

The mexican pharmacy chain farmacias similares, led by víctor gonzález herrera, has started its expansion strategy to japan through digital marketing and brand adaptation. With 10,000 branches in latin america, the company aims to replicate its generic medicines model in a highly regulated market. This move marks a milestone in its internationalization beyond the american continent.

Farmacias similares, latin america's largest pharmacy chain with 10,000 branches, has solidified its business model focused on generic medicines and adjacent medical consultations. This strategy has driven its growth in mexico and enabled prior explorations in central america.

Now, under the leadership of víctor gonzález herrera, the company is projecting its entry into the japanese market through a focus on digital marketing and social networks. According to the 'de jefes' column published on february 16, 2026, in el financiero, the firm will adapt its corporate identity and emblematic characters, such as doctor simi, under a local japanese aesthetic to connect with asian consumers.

"This growth phase seeks to diversify the group's income and validate the scalability of its generic medicines business model in markets with high regulation and technological demand," the column states.

The japanese pharmaceutical market poses significant challenges, with a highly regulated health system and strong presence of national pharmaceuticals. To enter, farmacias similares would need to comply with regulations from the pharmaceuticals and medical devices agency (pmda) and adapt to the pricing structure of the japanese health system. Sector experts emphasize the need for local alliances, rigorous sanitary certifications, and adaptation to advanced technological standards, given the high entry barriers for imported generic medicines and complex sanitary norms.

This incursion represents an effort to position the brand and the recognition of doctor simi in one of the world's most robust economies, replicating operational success outside the americas.

Artikel Terkait

The Chamber of Deputies approved on Monday (2) the bill allowing medicine sales in pharmacies installed inside supermarkets, with rules for physical separation and pharmacist presence. The text, heading to presidential sanction, aims to facilitate access to medicines, especially in remote areas, but faces opposition from some deputies over public health risks.

Dilaporkan oleh AI

Shares of Japanese pharmaceutical companies fell in early Tokyo trading on Friday after U.S. President Donald Trump launched a website offering discounted prescription drugs. Major firms like Sumitomo Pharma, Chugai Pharmaceutical, and Takeda Pharmaceutical saw declines, dragging down the overall drugmaker sector. Trump had announced deals with 16 of the world's largest drugmakers on Thursday for most-favored-nation pricing in exchange for tariff exemptions.

In 2025, Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms, totaling US$135.7 billion, up from 94 deals worth US$51.9 billion in 2024. Data released last week by China's National Medical Products Administration (NMPA) shows the number and value of these deals hit record highs, driven by dozens of multibillion-dollar agreements involving Hong Kong and mainland China-listed firms and international giants.

Dilaporkan oleh AI

Three major Japanese convenience store operators have reported growth in group operating profits for the March-November 2025 period. Seven & I Holdings, Lawson, and FamilyMart each posted gains driven by various strategies.

 

 

 

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak